CCR5 deficiency in the tumor microenvironment (TME) abrogates the survival efficacy of a total tumor mRNA immunotherapy platform for the treatment of glioblastoma.

CCR5 Deficiency in the Tumor Microenvironment (TME) Abrogates the Survival Efficacy of a Total Tumor Mrna Immunotherapy Platform for the Treatment of Glioblastoma